Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mary L Disis

Showing results (131-140 of 189) with videos related to

Pageof 19
Sort By:
Cancer Immunology, Immunotherapy : CII|October 29, 2013
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancersMary L Disis, Yushe Dang, Andrew L Coveler, et al.
Oncotarget|December 16, 2016
Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigensLatha B Pathangey, Dustin B McCurry, Sandra J Gendler, et al.
Molecular Cancer Therapeutics|March 6, 2008
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunityVivian Goodell, James Waisman, Lupe G Salazar, et al.
Vaccines|February 26, 2025
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast CancerWilliam R Gwin, Lupe G Salazar, James Y Dai, et al.
Journal of Translational Medicine|September 21, 2011
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discoveryDavide Bedognetti, James M Balwit, Ena Wang, et al.
Journal of Translational Medicine|June 3, 2014
Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancerJianning Mao, Jon Ladd, Ekram Gad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCCHailing Lu, Gregory N Dietsch, Maura-Ann H Matthews, et al.
Cancer Research|June 20, 2015
An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease PathogenesisHiroyuki Katayama, Clayton Boldt, Jon J Ladd, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2003
Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cellsAnnemieke Dols, Sybren L Meijer, Hong-Ming Hu, et al.
Breast Cancer Research and Treatment|August 9, 2014
Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic miceEun-Young Gil, Uk-Hyun Jo, Hye Jin Lee, et al.
Pageof 19

Showing results (131-140 of 189) with videos related to

Sort By:
Pageof 19
Cancer Immunology, Immunotherapy : CII|October 29, 2013
HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancersMary L Disis, Yushe Dang, Andrew L Coveler, et al.
Oncotarget|December 16, 2016
Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigensLatha B Pathangey, Dustin B McCurry, Sandra J Gendler, et al.
Molecular Cancer Therapeutics|March 6, 2008
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunityVivian Goodell, James Waisman, Lupe G Salazar, et al.
Vaccines|February 26, 2025
A Phase II Study of Denileukin Diftitox in Patients with Advanced Treatment Refractory Breast CancerWilliam R Gwin, Lupe G Salazar, James Y Dai, et al.
Journal of Translational Medicine|September 21, 2011
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discoveryDavide Bedognetti, James M Balwit, Ena Wang, et al.
Journal of Translational Medicine|June 3, 2014
Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancerJianning Mao, Jon Ladd, Ekram Gad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2011
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCCHailing Lu, Gregory N Dietsch, Maura-Ann H Matthews, et al.
Cancer Research|June 20, 2015
An Autoimmune Response Signature Associated with the Development of Triple-Negative Breast Cancer Reflects Disease PathogenesisHiroyuki Katayama, Clayton Boldt, Jon J Ladd, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 5, 2003
Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cellsAnnemieke Dols, Sybren L Meijer, Hong-Ming Hu, et al.
Breast Cancer Research and Treatment|August 9, 2014
Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic miceEun-Young Gil, Uk-Hyun Jo, Hye Jin Lee, et al.
Pageof 19